Dr. Cohen Discusses the KEYNOTE-040 Trial in Head and Neck Cancer

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the phase III KEYNOTE-040 trial in head and neck cancer.

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the phase III KEYNOTE-040 trial in head and neck cancer.

The KEYNOTE-040 trial evaluated pembrolizumab (Keytruda) versus standard of care in patients with recurrent or metatstaic head and neck squamous cell carcinoma.

This was the first effort in a randomized setting to demonstrate benefit, though statistically, it did not meet its endpoint.

Related Content:

OncLive TVHead & Neck CancersImmuno-Oncology
ASTRO Issues Clinical Practice Guideline For Radiation Therapy in HPV-Associated OPSCC
Dr Tarantino on the Safety of T-DXd and T-DM1 in HER2+ Breast Cancer
Dr Davis on the Potential For ADCs to Continue to Reshape Breast Cancer Treatment